Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study (PREDICT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03056612
Recruitment Status : Completed
First Posted : February 17, 2017
Last Update Posted : April 12, 2019
Sponsor:
Information provided by (Responsible Party):
Jonel Trebicka, European Foundation for Study of Chronic Liver Failure

Brief Summary:
The aim of this study is to assess prospectively the critical period prior to the development of Acute-on-Chronic Liver Failure (ACLF) (1), to uncover mechanistic and pathophysiological processes associated with the development and clinical course of ACLF (2) and to identify the precipitating events of ACLF (3).

Condition or disease Intervention/treatment
Liver Cirrhosis With Acute Decompensation Other: Observation protocol

Detailed Description:
  1. This International-European, investigator-initiated, multicenter, prospective, observational study will be performed in centers that belong to the European Foundation for the Study of Chronic Liver failure (EF-CLIF)-European Association for Study of the Liver (EASL)-EASL-CLIF Consortium.
  2. The population of patients would include ca. 1,200 cirrhotic patients over a twelve-months period. These patients will be admitted/referred to the study center because of acute decompensation (AD) of cirrhosis (ascites, overt encephalopathy, GI-hemorrhage, new onset of non-obstructive jaundice and/or bacterial infections), without ACLF (as defined according to the Canonic study ) at hospitalization.
  3. After the enrolment visit, the patients will be stratified into two groups: Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50) and in Group 2 patients with low risk of ACLF (CLIF-C AD score <50). The whole cohort will be followed for 3 months, while Group 1 will be followed more closely. Development of ACLF is an end-point and in this case a final visit 7-10 days after ACLF development is planned. Data on liver transplantation, mortality and causes of mortality 3 months, 6 months and 12 months will be collected in the whole cohort.
  4. Prospective collection of biological material and performance of ancillary studies investigating predictors for development and pathogenesis of ACLF.

Specific goals of the study:

  • To identify early clinical predictors, biomarkers, mechanisms and precipitating events during the critical period prior to and involved in the development and clinical course of ACLF (with special emphasis to medical trajectory and drug history) in patients admitted/referred to study center with acute decompensation of cirrhosis (ascites, GI-hemorrhage, overt encephalopathy, new onset of non-obstructive jaundice and/or bacterial infections) and the chronological relationship of the events with occurrence and dynamics of ACLF development.
  • To develop a score predicting ACLF development (CLIF-PREDICT score) and assess 28-day, 90-day, 6-month and 1-year all-cause mortality in cirrhotic patients with acute AD, but without ACLF.
  • To serve as a core (hub) study for prospective ancillary studies regarding diagnosis, prognosis and pathogenesis of AD and ACLF.

Main endpoints

  • Assessment of the critical period prior to ACLF development

    • Characterization of mechanisms responsible for ACLF development
    • Predictors of clinical course dynamics of ACLF evolution and mortality.
    • Identification and role of precipitating events for ACLF development.
  • To elaborate a CLIF-PREDICT score 2. Secondary endpoints
  • Prospective core ancillary studies to investigate the pathogenesis of ACLF.

Layout table for study information
Study Type : Observational
Actual Enrollment : 1314 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study
Actual Study Start Date : March 31, 2017
Actual Primary Completion Date : July 31, 2018
Actual Study Completion Date : October 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis

Group/Cohort Intervention/treatment
Group 1
Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50)
Other: Observation protocol
The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.

Group 2
Group 2 patients with low risk of ACLF (CLIF-C AD score <50)
Other: Observation protocol
The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.

ACLF
ACLF-patients were specified the patients who were admitted at hospital with ACLF,
Other: Observation protocol
The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.




Primary Outcome Measures :
  1. Number of patients developing ACLF within 12 weeks and severity of ACLF development [ Time Frame: 12 weeks ]
    • Characterization of mechanisms responsible for ACLF development
    • Predictors of clinical course dynamics of ACLF evolution and mortality.
    • Identification and role of precipitating events for ACLF development.


Secondary Outcome Measures :
  1. Score to PREDICT ACLF [ Time Frame: 12 weeks ]
    -Calculate a Score to predict ACLF


Biospecimen Retention:   Samples With DNA
peripheral serum, plasma, PBMC/PMN, urine, hair (in case of alcohol abuse), ascites (if any), stool, saliva


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The population of patients would include ca. 1,200 cirrhotic patients over a twelve-months period. These patients will be admitted/referred to the study center because of acute decompensation of cirrhosis (ascites, overt encephalopathy, GI-hemorrhage, new onset of non-obstructive jaundice and/or bacterial infections), without ACLF (as defined according to the CANONIC study ) at hospitalization.
Criteria

Inclusion Criteria:

The patients admitted/referred to study center with AD of cirrhosis (ascites, overt encephalopathy, new onset of non-obstructive jaundice, GI-hemorrhage and/or bacterial infections), but without ACLF (as defined according to the CANONIC study) at study inclusion.

Exclusion Criteria:

  1. Presence of ACLF at inclusion;
  2. Pregnancy;
  3. Age <18 years;
  4. Patients with acute or subacute liver failure without underlying cirrhosis;
  5. Patients with cirrhosis who develop decompensation in the postoperative period following partial hepatectomy;
  6. Evidence of current malignancy except for non-melanocytic skin cancer and hepatocellular carcinoma within Milan criteria;
  7. Presence or history of severe extra-hepatic diseases (e.g., chronic renal failure requiring hemodialysis, severe heart disease (NYHA > II); severe chronic pulmonary disease (GOLD > III), severe neurological and psychiatric disorders);
  8. HIV-positive patients
  9. Previous liver or other transplantation
  10. Admission/referral of more than 72 hours before inclusion
  11. Patients who decline to participate or who cannot provide prior written informed consent and when there is documented evidence that the patient has no legal surrogate decision maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent;
  12. Physician´s denial (e.g. the investigator considers that the patient will not follow the protocol scheduled).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03056612


Locations
Show Show 45 study locations
Sponsors and Collaborators
Jonel Trebicka
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jonel Trebicka, Principal Investigator EFCLIF, European Foundation for Study of Chronic Liver Failure
ClinicalTrials.gov Identifier: NCT03056612    
Other Study ID Numbers: PREDICT
First Posted: February 17, 2017    Key Record Dates
Last Update Posted: April 12, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Liver Failure
End Stage Liver Disease
Acute-On-Chronic Liver Failure
Fibrosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Hepatic Insufficiency
Liver Failure, Acute